Floatz logo

VALSARTAN

Cognitive Decline

Hospital Moinhos de VentoSmall moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

14 Active assets in the Cognitive Decline cohort.

Asset / SponsorPhaseRating
LEVODOPA
Vanderbilt University Medical Center
Phase 4BB
Lipitor
Monash University
Phase 4BB
Arestin
University of Cincinnati
Phase 2BB
FLORTAUCIPIR
University of Pennsylvania
Phase 2BB
Micardis®
The George Institute
Phase 3B

View all 19 →

Same molecule, other indications

VALSARTAN is also rated in:

hypertensive disorderDormant
BBB
Indicative ·
77 / 100
View asset →
abdominal obesity-metabolic syndromeDormant
BB
Indicative ·
69 / 100
View asset →
essential hypertensionDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →